Navamedic ASA receives approval for conditional reimbursement for Mysimba® in Finland
Oslo, 7 September 2021 – Navamedic ASA (OSE: NAVA) receives approval for conditional reimbursement for Mysimba® in Finland from 1 November 2021. The company expects accelerated growth of Mysimba® in the Finnish market following the reimbursement, further fueled by Navamedic’s successful patient support program planned for launch in Finland in 2022.Mysimba® is the first obesity treatment of its kind, combining both an oral medicin with a digital and custom-made patient support program to maximise patients’ success in treatment. Mysimba® reduces hunger and cravings, and provides control over